Astria Therapeutics Inc. Unveils Corporate Presentation Highlighting Advancements in Allergy and Immunology Therapies

Reuters

08/13

<a href="https://laohu8.com/S/ATXS">Astria Therapeutics Inc</a>. Unveils Corporate Presentation Highlighting Advancements in Allergy and Immunology Therapies

Astria Therapeutics Inc. has released a corporate presentation detailing its ongoing efforts in developing treatments for hereditary angioedema $(HAE)$ and atopic dermatitis. The presentation highlights Astria's progress with navenibart, a half-life extended monoclonal antibody inhibitor of plasma kallikrein, which is currently undergoing the ALPHA-ORBIT Phase 3 trial. This trial aims to support the registration of Q3M and Q6M navenibart administration as a potential market-leading treatment for HAE. The presentation also outlines Astria's pipeline milestones, including initial results from the ALPHA-SOLAR study anticipated in Q2 2025. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559621592"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559621592\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559621592?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 04:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559621592","market":"us","top_or_hot":-1,"title":"Astria Therapeutics Inc. Unveils Corporate Presentation Highlighting Advancements in Allergy and Immunology Therapies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATXS\">Astria Therapeutics Inc</a>. Unveils Corporate Presentation Highlighting Advancements in Allergy and Immunology Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has released a corporate presentation detailing its ongoing efforts in developing treatments for hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> and atopic dermatitis. The presentation highlights Astria's progress with navenibart, a half-life extended monoclonal antibody inhibitor of plasma kallikrein, which is currently undergoing the ALPHA-ORBIT Phase 3 trial. This trial aims to support the registration of Q3M and Q6M navenibart administration as a potential market-leading treatment for HAE. The presentation also outlines Astria's pipeline milestones, including initial results from the ALPHA-SOLAR study anticipated in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astria Therapeutics Inc. Unveils Corporate Presentation Highlighting Advancements in Allergy and Immunology Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstria Therapeutics Inc. Unveils Corporate Presentation Highlighting Advancements in Allergy and Immunology Therapies\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-13 04:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATXS\">Astria Therapeutics Inc</a>. Unveils Corporate Presentation Highlighting Advancements in Allergy and Immunology Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has released a corporate presentation detailing its ongoing efforts in developing treatments for hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> and atopic dermatitis. The presentation highlights Astria's progress with navenibart, a half-life extended monoclonal antibody inhibitor of plasma kallikrein, which is currently undergoing the ALPHA-ORBIT Phase 3 trial. This trial aims to support the registration of Q3M and Q6M navenibart administration as a potential market-leading treatment for HAE. The presentation also outlines Astria's pipeline milestones, including initial results from the ALPHA-SOLAR study anticipated in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATXS","symbol_name":"Astria Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL1GwWRw:1","article_id":"2559621592","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559621592","pubTimestamp":1755029640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Astria Therapeutics Inc. has released a corporate presentation detailing its ongoing efforts in developing treatments for hereditary angioedema  and atopic dermatitis. The presentation highlights Astria's progress with navenibart, a half-life extended monoclonal antibody inhibitor of plasma kallikrein, which is currently undergoing the ALPHA-ORBIT Phase 3 trial. This trial aims to support the registration of Q3M and Q6M navenibart administration as a potential market-leading treatment for HAE. The presentation also outlines Astria's pipeline milestones, including initial results from the ALPHA-SOLAR study anticipated in Q2 2025. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATXS":"Astria Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Astria Therapeutics Inc.发布公司演示文稿，重点介绍过敏和免疫学疗法的进步","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATXS":0.9},"content_text":"Astria Therapeutics Inc. Unveils Corporate Presentation Highlighting Advancements in Allergy and Immunology Therapies\n    \n\n        Astria Therapeutics Inc. has released a corporate presentation detailing its ongoing efforts in developing treatments for hereditary angioedema $(HAE)$ and atopic dermatitis. The presentation highlights Astria's progress with navenibart, a half-life extended monoclonal antibody inhibitor of plasma kallikrein, which is currently undergoing the ALPHA-ORBIT Phase 3 trial. This trial aims to support the registration of Q3M and Q6M navenibart administration as a potential market-leading treatment for HAE. The presentation also outlines Astria's pipeline milestones, including initial results from the ALPHA-SOLAR study anticipated in Q2 2025. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}